Eli Lilly and Company Loses Appeal in Gemzar Patent Case

WSJ -- A federal appeals court ruled Wednesday that an Eli Lilly Co. patent for anti-cancer drug Gemzar is invalid, a decision that may clear the way for generic competition to the drug late this year.